This article presents a comprehensive overview of systematic procedure for establishing and validating an in vitro -in vivo correlation (IVIVC) level A, B, and C. It encompasses all experimental, statistical and mathematical concepts of IVIVC development and its validation. A Level A IVIVC is an important mathematical tool that can help to save time and cost during and after the development of a formulation.
INTRODUCTION
In recent years, a number of drugs are being developed. Thus there is a growing need of pharmacokinetic studies; subsequently it has become a very tedious, expensive and time consuming task to collect and handle huge pharmacokinetic data. It is therefore, useful to develop pharmacokinetic simulation models for the prediction of pharmacokinetic parameters. Pharmacokinetic simulation model is defined as a computational and/or mathematical tool that interprets drug kinetics in living environment under specific conditions .
In addition to routine quality control tests, comparative dissolution test have been utilized to waive off bioequivalence requirements called biowaiver studies, for lower strength of a formulation. For a biowaiver study, a dissolution profile should be established and characterized using model dependent and independent approaches. Biowaiver study is generally conducted for multiple strengths with different release rates, after the *Corresponding author. E-mail: gmdogar356@gmail.com. Tel: +92-314-2082826. Fax: +92-992-383441. approval of a bioequivalence study performed on one strength . For the prediction of in vivo performance of a formulation, the use of dissolution test as a quality control tool is significantly increased if an in vitro-in vivo correlation (IVIVC) is developed. The application of the IVIVC involves the selection of the biorelevant in vitro dissolution test method in bioequivalence studies . Another important use of the validated IVIVC is to provide an explanation for a biowaiver during scale-up or post approval changes. Certainly, a biowaiver will only be awarded if the prophecy of the in vivo act of the formulation with the modified in vitro release rate remains bioequivalent with that of the originally tested formulation .
The IVIVC for a formulation is a mathematical relationship between an in vitro property of the formulation and its in vivo act. The in vitro drug release profiles commonly act as distinguished in vitro characteristic. Whereas, the in vivo act is elaborated by plasma drug profiles, these profiles are then treated mathematically to assess whether a correlation exists; a correlation can generally be expected when drug release from the formulation is the step controlling the subsequent absorption kinetics . The IVIVC assessment depends on mean in vitro and in vivo data. Based on regulatory guidelines, the in vitro profiles are regarded acceptable for an IVIVC: (i) When the dissolution rate is a mean of twelve individual determinations and (ii) the coefficient of variation at each sampling point is less than 10%; however the initial release data may exhibit a larger variability .
The in vitro dissolution testing is used to accept or reject formulation. The acceptable formulations are considered bioequivalent in terms of in vivo performance and vice versa. For the establishment of IVIVC, a minimum of three formulations with different release rate are required. In addition, a reliable and discriminating in vitro dissolution test is also required which can be established changing its different variables so that it may perform as in vivo environments. Before in vivo performance of a formulation, the discriminating dissolution test can be utilized as a quality assurance tool . Briefly based as IVIVC, dissolution test acts as surrogate of the bioavailability study (U.S. Department of Health and Human Services, 1997) .
A theoretical basis has been developed for developing correlation between in vitro dissolution and in vivo bioavailability depending on the solubility and permeability of drug. Using this approach, solubility and permeability of different representative drugs have been studied and is presented in a biopharmaceutics drug classification system (Table 1) The Biopharmaceutics Classification System (BCS) is a predictive approach for developing correlation between physicochemical characteristics of a drug formulation and in vivo bioavailability. The BCS is not a direct IVIVC.
The IVIVC is calculated from in vitro and in vivo data of the same formulation using some mathematical functions based on the type of parameters employed. The IVIVC is Level C correlation is a weak single point relationship having no reflection of dissolution or plasma profile and compares the amount of drug dissolved at one dissolution time-point to one pharmacokinetic parameter like t 60% to AUC. Due to the involvement of multiple time points multiple times, multiple level C is more producible than level C. It relates one or many pharmacokinetic parameters to the quantity of drug dissolved at various time points. Level D correlation is helping in the development of a formulation. It is a rank order analysis which is not considered as a formal correlation (U.S. Department of Health and Human Services, 1997) .
Over the last one decade, the establishment and validation of IVIVC has extensively been studied U.S. Department of Health and Human Services, 1997; . A validated IVIVC not only plays an important role in formulation development but can also be used to predict the in vivo performance of a dosage form that has been developed according to a predefined methodology. Thus the validation of an IVIVC is as critical as the finding of a discriminating and specific . This article gives an overview of pharmaceutical, experimental, mathematical and statistical concepts for establishing in vitro-in vivo correlation.
METHODOLOGY Formulations
To develop IVIVC, commonly three formulations with different release rates are used; the formulations are abbreviated as follows:
1. Fast release formulation 2. Medium release formulation 3. Slow release formulation
In case of tablets, the quantity of polymer and/or the binder, compression force and the blending efficiency are usually varied to design formulations with different release rates (U.S. Department of Health and Human Services, 1997). Subsequently, it is mandatory to evaluate the formulations for elaborating whether their physicochemical properties like formulation assay, flow characteristics and compressibility, fulfill their compendial requirements (Shargel et al., 2005) . For the establishment of an IVIVC, the release governing excipients in the formulations should be similar. Preferably, in vitro dissolution profiles should be determined with different dissolution test conditions. The in vitro dissolution profiles leading to an IVIVC with the smallest prediction error (%) is then opted for further use as it is believed most bio-indicative .
RESULTS
To illustrate the statistical and mathematical concept of IVIVC development and its validation, the following simulated data has been adopted (Tables 2 to 4 
DISCUSSION

Obtention of in vitro dissolution data
A sensitive and reliable in vitro dissolution method is used for determining the quality of a formulation. Since the dissolution test is emerging as a surrogate for in vivo bioequivalence study rather than a traditional quality control tests . Therefore a reliable in vitro dissolution test for a drug substance is necessary for the development of IVIVC. Such a dissolution method can be developed by serial modifications in dissolution medium like the addition of a surfactant. After development of a reasonable dissolution medium, the in vitro dissolution testing is performed for suitable time period on the formulations selected. The dissolution samples are analyzed spectrophotometrically or chromatographically, to find out the amount of drug released. Consequently, the drug release versus time profiles are obtained for correlating with in vivo data. This data exhibits the fraction of drug dissolved at different time points.
Analysis of dissolution data
For the analysis of dissolution data, various model Table 4 . Values of AUC, MRT, t50% and MDT for fast, medium and slow release formulations. dependent and independent approaches are utilized. Out of model independent approaches, similarity factor analysis (a pair wise procedure) is commonly chosen to compare the dissolution profiles. The similarity factor (f 2 metric) analysis is conducted using following equation (Rasul et al., 2010) :
Formulation
In vivo parameter In vitro parameter AUC (µg.h/ml) MRT (h) t50% (h) MDT (h)
where, R t and T t are the cumulative percentage dissolved at time point "t" for reference and test products, respectively and "p" is the number of pool points.
The similarity factor is a logarithmic reciprocal square root transformed of the sum of the squared error and is a measurement of the similarity in the percentage dissolution between the two plots ). The two compared dissolution profiles are considered similar if f 2 > 50, and the mean difference between any dissolution sample not being greater than 15% (U.S. Department of Health and Human Services, 1997) .
Mean dissolution time, a model independent approach, would be calculated from dissolution data to determine level B correlation by the following equation ):
where "m" stands for the amount of drug dissolved at time "t".
For level C correlation, time required for a specific value of mean dissolution like t 50% (time required to dissolve 50% of total drug) is required which is calculated from the curve of zero order equation (U.S. Department of Health and Human Services, 1997).
Obtention of in vivo absorption data
To establish IVIVC, in vivo absorption data is also required which means that pharmacokinetic and bioavailability study is also to be done. Pharmacokinetic study reflects the performance of drug in body. It involves the study of the influence of body on the drug, that is, absorption, distribution, metabolism and excretion. Where as the bioavailability indicates the extent to which a drug reaches systemic circulation and is commonly assessed by evaluating AUC (area under plasma drug concentration-time curve), C max (maximum plasma drug concentration) and t max (time required to achieve C max ) .
Generally, single dose cross over experimental design with a washout period of one week, is adopted to obtain absorption data for establishing IVIVC. Thus for three formulations with different release rates, a three treatment cross over study design is allocated. For ethical reasons, the subject panel should be homogenous and consist of appropriate number of healthy young volunteers, not less than six . However, the size of subject panel should depend on the difference in the biological data.
The volunteers receive formulations according to study design and blood sampling is conducted according to good clinical practice (European Medicines Agency, 2009) and Helsinki declaration for human use in experimentation (World Medical Association Declaration of Helsinki, 2008) . The bio-analysis of collected blood samples is conducted using validated analytical methods. The plasma drug concentration data is plotted against time points, and subsequently this curve is used to calculate pharmacokinetic parameters such as AUC, AUMC, C max, T max and K e (elimination rate constant) using an appropriate pharmacokinetic model through manual calculations or suitable software like Kinetica ® (European Medicines Agency, 2009.). Kinetica ® has convolution/-deconvolution modules as well as Wagner-Nelson and Loo-Riegelman modules.
Analysis of in vivo data
The association between the in vitro and in vivo data is stated mathematically by a linear or nonlinear correlation. But, the plasma drug concentration data cannot be related directly to the obtained in vitro release data; they are needed to be converted first to the fundamental in vivo release data using pharmacokinetic compartment model analysis or linear system analysis. Based on a pharmacokinetic compartment analysis, the in vivo absorption kinetics can be evaluated using various pharmacokinetic parameters. The linear system analysis method requires the availability of a unit input response .
To develop level A correlation, in vivo absorption profiles of the formulations from the individual plasma concentration versus time data are also evaluated using Wagner-Nelson equation (Shargel et al., 2005) For the establishment of level B correlation, mean residence time (MRT) is calculated from AUC and AUMC as the following :
MRT is the first moment of drug distribution phase in body. It indicates the mean time for drug substance to transit through the body and involves in many kinetic processes (U.S. Department of Health and Human Services, 1997) . While level C correlation is established using a pharmacokinetic parameter like AUC, C max or t max .
IVIVC development and its analysis
Level A IVIVC correlates the entire in vitro and in vivo profiles ). In order to develop level A correlation, the fraction of drug absorbed (F a ) for a formulation is plotted against its fraction of drug dissolved (F d ), where F a and F d are plotted along x-axis and y-axis, respectively. This curve provides basic information of the relationship between F a and F d , either it is linear or nonlinear. Moreover, plots can also be plotted in the form of combination of two formulations like (a) slow/ moderate (b) moderate / fast and (c) slow / fast or in combination of three formulations like fast/moderate/slow. Finally the regression analysis is performed for each curve to evaluate strength of correlation. The correlation is considered as efficient as the value of determination coefficient is closer to 1 (U.S. Department of Health and Human Services, 1997; World Medical Association Declaration of Helsinki, 2008; Aamir et al., 2010) .
The predictability of the correlation is analyzed by calculating its prediction error (%). As illustrated in regulatory context, the deviation between prediction and observation is assessed either with internal validation or with external validation (U.S. Department of Health and Human Services, 1997; . Internal validation elaborates the predictability of data that has been employed in the model development and is recommended for all IVIVC analysis (U.S. Department of Health and Human Services, 1997). External validation depends on how efficiently the IVIVC predicts additional data sets. This predictability is considered better than the internal one. External predictability is analyzed in the following conditions (U.S. Department of Health and Human Services, 1997):
1. When no conclusion is obtained from internal prediction. 2. When correlation is established for drugs having narrow therapeutic window. 3. When two formulations with different release rates are involved in correlation development.
The predictability of a correlation in regulatory context is characterized in terms of the prediction error (%) using AUC and C max as the following: or where, C max (pred) and AUC pred are calculated from the predicted plasma profiles while convolution technique is used to estimate predicted equation . C(t) is plasma profile. C δ is unit impulse response or concentration-time course resulting from immediate release of a unit amount of drug. It is calculated from intravenous bolus data or reference oral solution. While "u" is the variable of integration. X vitro represent drug input rate of oral solid dosage form.
According to FDA guidelines, the correlation is considered predictive if mean prediction error across formulations is less than 10% for AUC and C max and the prediction error (%) for any formulation is less than 15% for AUC and C max (U.S. Department of Health and Human Services, 1997) .
Level B correlation is developed between MDT and MRT of a formulation. The MDT and MRT are plotted along x-axis and y-axis, respectively. The regression analysis is performed for this curve also .
Level C correlation, a single point correlation, can be established by drawing a curve between t 50% and pharmacokinetic parameter are plotted along x-axis and y-axis, respectively following regression analysis .
Conclusion
There is extensive international harmony on the development of IVIVC and its analysis as revealed in the guidelines of FDA. There is, however, escalating awareness that some fundamentals of IVIVC establishment require to be reviewed mathematically, like equations involved in data calculations and sequence of their use is determined. In the future, there will be unremitting endeavors toward achieving in vitro -in vivo correlations, on a case-by-case basis for each drug or classes of drugs. A Level A IVIVC is an important mathematical tool that can help to save time and cost during and after the development of a formulation.
